Bedford Metals Announces Multi-Phase Work Program for Ubiquity Lake Uranium Project

benzinga.com VANCOUVER, British Columbia, May 28, 2024 (GLOBE NEWSWIRE) -- BFM (the "Company" or "Bedford") is pleased to announce its proposed multi-phase work program for its ,…

Globe Metals Advances Kanyika Project with $46M Plan

tipranks.com Globe Metals & Mining Limited (AU:GBE) has released an update. Globe Metals & Mining Limited has finalized a $46 million funding plan for Phase 1 o...

Shenzhen Expressway Completes Multi-Year Bond Issue

tipranks.com Shenzhen Expressway Co (HK:0548) has released an update. Shenzhen Expressway Corporation Limited has successfully issued Phase 1 of its 2024 corpor...

3 Lithium Stocks That Could Be Millionaire-Makers: May Edition

investorplace.com The rise of electric vehicles and the world’s transition away from fossil fuels has led to the emergence of lithium stocks to buy. These stocks could be millionaire-makers.…

California high-speed rail takes "major" step

newsweek.com The California High-Speed Rail Authority took one giant leap in the state's goal of building a railway that will connect San Francisco to downtown Los Angeles. On Friday,…

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

investorplace.com AKAN and THAT stock are leading our pre-market stock movers We’re diving into the biggest pre-market stock movers that traders need to know about on Friday morning! Moving…

Why Shiba Shootout Tops the List of Promising Meme Coins This Year

coinpedia.org The post Why Shiba Shootout Tops the List of Promising Meme Coins This Year appeared first on Coinpedia Fintech News In the cryptocurrency realm, few projects have managed…

Legacy tech costs UK.gov billions, Capgemini to help HMRC

theregister.com The UK's tax collector has awarded tech consultancy and service provider Capgemini a contract worth up to £245.5 million to keep legacy systems up and running. The award…

I-Mab’s Ragistomig Shows Promise in Phase 1 Trials

tipranks.com I-MAB (IMAB) has released an update. I-Mab, a biotech company specializing in cancer immunotherapies, has revealed promising Phase 1 clinical data ...

Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American…

benzinga.com CHS-114 shown to have an acceptable safety profile with no dose-limiting toxicities (DLTs) in heavily pretreated patients with solid tumors Selective depletion of peripheral…

Elicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024…

benzinga.com ELI-002 7P administered as a monotherapy was well tolerated and able to generate a ~100x mKRAS-specific expanded T cell response relative to baseline levels • ELI-002 7P…

NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Advanced Solid Tumors at the 2024 American Society of Clinical…

benzinga.com SNK02 has the potential to be a first-in-class cryopreserved allogeneic NK cell therapy for solid tumors that does not require lymphodepletion before administration, which…

I-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at ASCO 2024

benzinga.com Encouraging objective responses were observed in heavily pre-treated patients, including 1 complete response (CR) and 6 partial responses (PR), mainly in patients previously…

Theriva™ Biologics Announces Fast Track Designation Granted by the U.S. FDA for VCN-01 for the Treatment of Metastatic Pancreatic Cancer

benzinga.com ROCKVILLE, Md., May 23, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics TOVX, a diversified clinical-stage company developing therapeutics designed to treat cancer and related…

Traws Pharma's ICAR Poster Highlights Potency of COVID-19 Candidate

benzinga.com NEWTOWN, Pa., May 23, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. ("Traws" or "Traws Pharma"), a clinical stage biopharmaceutical company developing oral small molecules for…

Aerovate Therapeutics Presents Baseline Data from the Phase 2b Portion of the IMPAHCT Trial at the American Thoracic Society 2024 International Conference

benzinga.com Topline data from Phase 2b portion of IMPAHCT study to be released in June 2024 Enrollment into the Phase 3 portion of IMPAHCT continues at more than 120 sites globally…

'Bankless Onchain' Phase II: Mint Our History on Bankless

bankless.com Bankless NFTs are back with some help from Zora. Last year, Bankless entered the podcast collectibles space with a bang. Our was a novel journey into onchain media and gave…

Snoop Dogg to Auction Off His Own Memorabilia

variety.com It’s no mystery that music memorabilia is a booming business. The Gibson J-160E acoustic guitar on which John Lennon wrote many early Beatles hits went for $2.5 million at…

Intrommune Therapeutics Presents Oral Mucosal Immunotherapy Updates at Leading Industry Events

benzinga.com NEW YORK, May 21, 2024 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, Inc., a biotechnology company committed to developing a patient-friendly treatment platform for people…

Cathie Wood Pulls the Trigger on These 2 ‘Strong Buy’ Stocks

finance.yahoo.com Cathie Wood is famous for her singular investing style. Favoring high growth and disruptors, she often appears to be throwing caution to the wind and willing to tread where…

NKGN Stock Alert: The Alzheimer’s News That Has NKGen Biotech Soaring Today

investorplace.com NKGN stock is up on study clearance NKGen Biotech (NASDAQ:NKGN) stock is taking off on Monday after the clinical-stage biotechnology company got an update on its Phase 2…

U.S. Patent and Trademark Office Grants US Patent # 11,975,112 for "Treatment of Vomiting and Nausea with Minimum Dose of Olanzapine"

benzinga.com Olanzapine (ZYPREXA®) is an antipsychotic medication used to treat schizophrenia and bipolar disorder that is commonly used as anti-nausea off label medication. • Olanzapine…

Tiny but Mighty: 3 Small-Cap Stocks Crushing the Russell 2000

investorplace.com Unveiling small-cap stocks in the Russell 2000 poised for growth The mega-cap tech stocks have garnered much attention in recent months. However, certain smaller companies…

Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST

benzinga.com MALVERN, Pa., May 15, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") OCGN, a biotechnology company focused on discovering, developing, and commercializing…

Ocugen Provides Business Update with First Quarter 2024 Financial Results

benzinga.com All three first-in-class modifier gene therapy product candidates currently in the clinic with OCU400 Phase 3 in progress OCU400 on track to meet 2026 Biologics License…